Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) shot up 2% during trading on Monday . The stock traded as high as $2.75 and last traded at $2.55, with a volume of 54,950 shares trading hands. The stock had previously closed at $2.50.

Several brokerages recently commented on ABEO. FBR & Co reiterated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research note on Sunday, May 22nd. Zacks Investment Research cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 4th. Maxim Group reiterated a “buy” rating and issued a $6.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, May 17th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $17.00 price objective on shares of Abeona Therapeutics in a research note on Wednesday, May 18th.

The firm’s 50-day moving average is $2.63 and its 200-day moving average is $2.64. The firm’s market capitalization is $83.63 million.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.04. Analysts anticipate that Abeona Therapeutics Inc. will post ($0.59) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Royce & Associates LLC raised its stake in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned about 0.92% of Abeona Therapeutics worth $1,007,000 at the end of the most recent quarter.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.